BMJ  2007;334:120-123 (20 January), doi:10.1136/bmj.39024.487720.68

Feature

What have we learnt from Vioxx?

¹ Department of Medicine, Yale University School of Medicine, 333 Cedar Street, PO Box 208088, New Haven, CT 06520-8088, USA, ² Department of Geriatrics and Adult Development, Mount Sinai School of Medicine, New York, USA, ³ Never Again Consulting, Attleboro, MA, USA, ⁴ Department of Bio Med Community Health, Brown University, Providence, RI, USA

In October UK patients who had cardiovascular events while taking rofecoxib lost the right to fight Merck in the US for compensation. But researchers and journals can still benefit from this case if they learn from the mistakes, write Harlan Krumholz and colleagues

The first 150 words of the full text of this article appear below.

Rofecoxib (Vioxx) was introduced by Merck in 1999 as an effective, safer alternative to non-steroidal anti-inflammatory drugs for the treatment of pain associated with osteoarthritis. It was subsequently found to increase the risk of cardiovascular disease and withdrawn from the worldwide market. Merck now faces legal claims from nearly 30 000 people who had cardiovascular events while taking the drug.¹ The company has stated that it will fight each case, denying liability.² Our recent participation in litigation at the request of plaintiffs provided a unique opportunity to thoroughly examine and reflect on much of the accumulated court documents, research, and other evidence. This story offers important lessons about how best to promote constructive collaboration between academic medicine and industry.

Early suspicion of cardiovascular risk

Since the early development of rofecoxib, some scientists at Merck were concerned that the drug might adversely affect the cardiovascular system by altering the ratio of prostacyclin to thromboxane, which act . . . [Full text of this article]

The VIGOR study

Obscuring the risk

Short and long term use

Medical journals

Promoting constructive collaboration

Summary points

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Has the hunt for conflicts of interest gone too far? Yes

Thomas P Stossel
BMJ 2008 336: 476. [Extract] [Full Text] [PDF]

Direct to consumer advertising of drugs in Europe

Nicola Magrini and Maria Font
BMJ 2007 335: 526. [Extract] [Full Text] [PDF]

Merck appeals rofecoxib verdict

Janice Hopkins Tanne
BMJ 2007 334: 607. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Lo, B., Kriegstein, A., Grady, D. (2008). Clinical trials in stem cell transplantation: guidelines for scientific and ethical review. Clin Trials 5: 517-522 [Abstract]  
• Aldred, R. (2008). Ethical and Political Issues in Contemporary Research Relationships. Sociology 42: 887-903 [Abstract]  
• Hill, K. P., Ross, J. S., Egilman, D. S., Krumholz, H. M. (2008). The ADVANTAGE Seeding Trial: A Review of Internal Documents. ANN INTERN MED 149: 251-258 [Abstract] [Full text]  
• Ross, J. S., Hill, K. P., Egilman, D. S., Krumholz, H. M. (2008). Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation. JAMA 299: 1800-1812 [Abstract] [Full text]  
• Stossel, T. P (2008). Has the hunt for conflicts of interest gone too far? Yes. BMJ 336: 476-476 [Full text]  
• Magrini, N., Font, M. (2007). Direct to consumer advertising of drugs in Europe. BMJ 335: 526-526 [Full text]  
• Loscalzo, J. (2007). Entrepreneurship in the Medical Academy: Possibilities and Challenges in Commercialization of Research Discoveries. Circulation 115: 1504-1507 [Full text]  
• Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., Taubert, K. A. (2007). Use of Nonsteroidal Antiinflammatory Drugs: An Update for Clinicians: A Scientific Statement From the American Heart Association. Circulation 115: 1634-1642 [Full text]  

Rapid Responses:

Read all Rapid Responses

A great deal to learn

Radhika Vohra
bmj.com, 20 Jan 2007 [Full text]

Some day, we may have to swallow the bitter pill

Rajan TD
bmj.com, 20 Jan 2007 [Full text]

Hindsight

zahid bashir
bmj.com, 26 Jan 2007 [Full text]

We have not learnt enough

Edward Auersperg
bmj.com, 27 Jan 2007 [Full text]

competing toxicity-what about the gut?

Maarten Boers
bmj.com, 31 Jan 2007 [Full text]

correction: and what about the gut?

Maarten Boers
bmj.com, 2 Feb 2007 [Full text]

Aspirin versus acetaminophen for pain control in patients with cardiovascular and gastrointestinal risk factors

Michal R. Pijak
bmj.com, 6 Feb 2007 [Full text]

Assessing adverse events in randomised controlled trials : a challenge for methodologists

Isabelle Pitrou
bmj.com, 23 Feb 2007 [Full text]

On Selective Learning

Theordore V.H. Mayer
bmj.com, 24 Feb 2007 [Full text]

Re: On Selective Learning

Mark E. McConnell
bmj.com, 16 Mar 2007 [Full text]

Re: On Selective Learning

David S. Egilman, et al.
bmj.com, 9 Apr 2007 [Full text]